A major randomized controlled trial published in The New England Journal of Medicine has fundamentally challenged decades of established septic shock management protocols. The CENSER trial, involving over 1,500 patients across multiple international centers, demonstrates that early vasopressor therapy achieves outcomes equivalent to traditional aggressive fluid resuscitation—potentially reshaping practice in emergency departments and intensive care units worldwide.
The study randomized adults with septic shock to receive either early norepinephrine infusion with minimal fluids or standard 30ml/kg crystalloid boluses within the first hour of presentation. Results showed comparable 90-day mortality rates and organ dysfunction outcomes between both approaches, raising critical questions about current Surviving Sepsis Campaign guidelines that emphasize rapid fluid administration as first-line therapy.
These findings suggest that clinicians may have greater flexibility in septic shock management, with vasopressor-first strategies potentially reducing fluid overload complications while maintaining equivalent survival benefits. The trial’s implications could prompt significant revisions to international critical care protocols.
Read the full article on GMJ Newsroom.
Was this article helpful?
